Enanta Pharmaceuticals
ENTA
151 hedge funds and large institutions have $827M invested in Enanta Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 46 increasing their positions, 60 reducing their positions, and 15 closing their positions.
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
2% more funds holding
Funds holding: 148 → 151 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.14% less ownership
Funds ownership: 96.34% → 93.2% (-3.1%)
13% less capital invested
Capital invested by funds: $956M → $827M (-$129M)
23% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 60
73% less call options, than puts
Call options by funds: $897K | Put options by funds: $3.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$17.2M |
| 2 |
Millennium Management
New York
|
+$5.72M |
| 3 |
KAM
Krensavage Asset Management
New York
|
+$3.76M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.81M |
| 5 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.9M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$7.24M |
| 3 |
Renaissance Technologies
New York
|
-$5.02M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.74M |
| 5 |
BlackRock
New York
|
-$2.82M |
ENTA Hedge Fund Activity: Q2 2021 in Review
151 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2021, worth a combined $827M — down 13% from $956M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ENTA positions and 15 closed out — a net gain of 3 holders — while 46 added to existing stakes and 60 trimmed.
The largest buyer was Armistice Capital, adding an estimated $17.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $29.9M.
- 151 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2021, up from 148 in Q1 2021.
- Funds reported $827M of Enanta Pharmaceuticals stock for Q2 2021, down 13% quarter-over-quarter.
- 18 funds opened new Enanta Pharmaceuticals positions in Q2 2021 and 15 closed out, a net change of +3 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2021 was Armistice Capital, an estimated $17.2M added.
- The largest Enanta Pharmaceuticals seller in Q2 2021 was T. Rowe Price Associates, an estimated $29.9M sold.
Based on aggregated 13F filings for Q2 2021.